Nov 1, 2025 | News |
The Tribal Biotechnology & Health Consortium today submitted the completed post-market clinical validation of Rampart™ DL Matrix (Q4347) to the Centers for Medicare & Medicaid Services and all seven Medicare Administrative Contractors as a formal sovereign...
Oct 28, 2025 | News |
A STATEMENT FROM THE OFFICE OF THE CEO Issued by Clear Health Pass Holdings, LLC, as Authorized Tribal Agent It has come to the attention of Clear Health Pass Holdings, in its capacity as Authorized Tribal Agent for the Tribal Biotechnology & Health Consortium,...
Oct 13, 2025 | News |
The Centers for Medicare & Medicaid Services has issued Rampart™ DL Matrix (HCPCS Q4347), the only FDA-cleared tribally owned skin substitute in the Medicare system, on the Q4 2025 Average Sales Price file for Medicare Part B. The Q4 2025 ASP rate took effect for...
Sep 16, 2025 | News |
The Tribal Biotechnology & Health Consortium’s full sovereign submission on the CY 2026 Medicare Physician Fee Schedule has been posted publicly on Regulations.gov, the federal government’s official rulemaking record platform, under Comment ID CMS-2025-0304-13291....
Sep 12, 2025 | News |
The Tribal Biotechnology & Health Consortium today filed its formal sovereign comment on the proposed CY 2026 Medicare Physician Fee Schedule (CMS-1832-P), continuing a coordinated, multi-docket engagement with the Centers for Medicare & Medicaid Services. The...
